Plasmodium falciparum Malaria Clinical and Parasitological Outcomes after In-vivo Artemether- Lumefantrine (AL) Treatment at Bushenyi District Uganda

Simple item page
dc.contributor.authorNyabayo Maniga, Josephat
dc.contributor.authorAliero, Adamu Almustapha
dc.contributor.authorNtulume, Ibrahim
dc.contributor.authorOkech, Matilda Angela
dc.contributor.authorClaire Mack, Mugasa
dc.date.accessioned2022-11-23T12:08:59Z
dc.date.available2022-11-23T12:08:59Z
dc.date.issued2018
dc.description.abstractThe aim of this study was to determine the Plasmodium falciparum malaria clinical and parasitological outcomes after in-vivo Artemether-Lumefantrine (AL) treatment at Bushenyi District Uganda. Study Design: This was a one-arm prospective longitudinal health point survey. Place and Duration: This study was carried out in Bushenyi District Uganda as from May 2017 to August 2017 for a period of four months at the selected four health centers. Methodology: A cohort of 283 human participants who had been confirmed of Plasmodium falciparum malaria was followed for a period of 28 days after treatment with Artemether-Lumefatrine (AL) drug. The follow up was done at fixed check up visits i.e. day 0, 1, 2, 3, 7, 14, 28. Parasitological and clinical evaluations were done at each subsequent follow up days. Consequently they were requested to fill a questionnaire which had aspects of malaria infection. Results: Out of the 283 participants recruited to this study 194 (68.6%) participants completed the follow up schedules while 89 (31.4%) were withdrawn from the study. There was adequate clinical and parasitological response (ACPR) among 53(27.3%) participants. There was late parasitological failure (LPF) among 43 (22.2%) participants. There was late clinical failure (LCF) among 23(11.9%) participants and there was early treatment failure (ETF) among 75 (38.7%) participants Conclusion: There was suspected Artemether- Lumefantrine (AL) poor response to Plasmodium falciparum malaria in the study area after 8 years of introduction to Uganda as a drug of choice for treatment of uncomplicated malaria. Those aged 5 years and below were 2.28 times more likely to present LCF as a clinical treatment outcome compared to other age groups when other factors were held constant. Molecular confirmation of the suspected resistance needs to be conducted in the collected Plasmodium falciparum isolates.en_US
dc.identifier.citationManiga, J. N., Aliero, A. A., Ibrahim, N., Okech, M. A., & Mack, M. C. (2018). Plasmodium falciparum malaria clinical and parasitological outcomes after in-vivo Artemether-Lumefantrine (AL) treatment at Bushenyi District Uganda. Int J Trop Dis Health, 8, 10-18. DOI: 10.9734/IJTDH/2018/39642en_US
dc.identifier.other10.9734/IJTDH/2018/39642
dc.identifier.urihttps://nru.uncst.go.ug/handle/123456789/5373
dc.language.isoenen_US
dc.publisherInternational Journal of Tropical Disease & Healthen_US
dc.subjectPlasmodium falciparumen_US
dc.subjectCohorten_US
dc.subjectDrug resistanceen_US
dc.subjectArtemether- Lumefantrine (AL)en_US
dc.subjectUgandaen_US
dc.titlePlasmodium falciparum Malaria Clinical and Parasitological Outcomes after In-vivo Artemether- Lumefantrine (AL) Treatment at Bushenyi District Ugandaen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Plasmodium falciparum Malaria.pdf
Size:
2.18 MB
Format:
Adobe Portable Document Format
Description:
Article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Medical and Health Sciences